AI Article Synopsis

  • This study investigates the effects of binase, a ribonuclease, on the sensitivity to interferon and the rate of apoptosis in HPV-infected SiHa cervical cancer cells.
  • Results showed that binase treatment led to increased apoptosis and decreased levels of E6 and E7 viral oncoproteins, while boosting the expression of tumor suppressors p53 and pRb.
  • When combined with interferon alpha 2b, binase further enhanced interferon sensitivity in HPV-positive cells, but did not have the same effect on HPV-negative C33A cells, indicating its specific action against HPV-related cancer.

Article Abstract

In this study, we determined whether binase, a ribonuclease from , increases interferon sensitivity and apoptosis in SiHa cervical cancer cells infected with high-risk human papilloma virus (HPV) strain 16. Binase treatment increased SiHa cell apoptosis in a time- and concentration-dependent manner, as determined by flow cytometry, WST tests and real time xCelligence cell index analysis. Binase-treated SiHa cells showed reduced expression of E6 and E7 viral oncoproteins and increased expression of their intracellular targets, p53 and pRb. Combined treatment with binase and IFNα2b enhanced the interferon sensitivity of HPV-positive SiHa cells. By contrast, combined treatment with binase and IFNα2b in HPV-negative C33A cervical cancer cells, which do no expess E6 and E7, elicited no changes in interferon sensitivity or p53 and pRb expression. These findings suggest binase enhances interferon sensitivity and apoptosis in HPV-positive SiHa cervical cancer cells by suppressing E6 and E7 viral protein expression.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641160PMC
http://dx.doi.org/10.18632/oncotarget.20199DOI Listing

Publication Analysis

Top Keywords

interferon sensitivity
20
sensitivity apoptosis
12
siha cervical
12
cervical cancer
12
cancer cells
12
binase treatment
8
increases interferon
8
apoptosis siha
8
human papilloma
8
papilloma virus
8

Similar Publications

Objectives: To investigate the association between quantitative T-SPOT.TB values and the risk of incident and prevalent tuberculosis disease (TBD), identify risk factors, and evaluate test accuracy.

Methods: This retrospective cohort study followed patients tested consecutively with T-SPOT.

View Article and Find Full Text PDF

Background: Kidney transplant (KT) recipients at intermediate risk for cytomegalovirus (CMV) infection constitute a potential target for individualized prevention strategies informed by the CMV-specific cell-mediated immunity (CMV-CMI). The optimal method for the functional assessment of CMV-CMI in this group remains unclear.

Methods: We included 74 CMV-seropositive KT recipients that did not receive T-cell-depleting induction and were managed by preemptive therapy.

View Article and Find Full Text PDF

Background: Myelofibrosis (MF) is a clonal haematopoietic disease, with median overall survival for patients with primary MF only 6.5 years. The most frequent gene mutation found in patients is JAK2, causing constitutive activation of the kinase and activation of downstream signalling.

View Article and Find Full Text PDF

Psoriasis is a chronic, immune-mediated disease. The systemic inflammation triggered by psoriasis contributes significantly to increased cardiovascular risk. While various treatments completely clear the skin, the associated effects on systemic inflammation are not yet clear.

View Article and Find Full Text PDF

Evaluation of QuantiFERON-TB Gold for the Diagnosis of Infection in HTLV-1-Infected Patients.

Viruses

November 2024

Laboratório Avançado de Saúde Pública, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (Fiocruz-BA), Salvador 40296-710, Bahia, Brazil.

Human T-cell leukemia virus type 1 (HTLV-1) is associated with an increased risk of tuberculosis (TB). This study aimed to evaluate the performance of the QuantiFERON-TB Gold (QFT) test for the diagnosis of (MTB) infection in HTLV-1-infected individuals. HTLV-1-infected participants were divided into four groups: HTLV-1-infected individuals with a history of tuberculosis (HTLV/TB), individuals with positive HTLV and tuberculin skin tests (HTLV/TST+) or negative TST (HTLV/TST-), and HTLV-1-negative individuals with positive TST results (HN/TST+).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!